Feature | April 18, 2014

SEARCH-AF Trial Shows Pharmacists Can Use Pocket ECG to Detect AFib, Stroke Risk

Heart monitor identifies asymptomatic patients with unknown atrial fibrillation at high risk of stroke

April 18, 2014 — AliveCor announced the online publication of study results of the SEARCH-AF study. The SEARCH-AF study, conducted in Australia, screened 1,000 customers over 65 years old for atrial fibrillation (AF) in 10 community pharmacies in suburban Sydney.

The AliveCor heart monitor was used to capture 30-60 second ECG (electrocardiogram) recordings and wirelessly transmit the recordings to study cardiologists. This simple method of remote ECG capture enabled study cardiologists to identify patients at risk of stroke because of unknown AF, and flag them for additional evaluation. New AF was identified in 1.5 percent of the people screened, all at high risk of stroke. Most of the people with newly discovered AF had no symptoms, and may never have sought medical advice.

This study highlights one application of mobile ECG technology that can help facilitate cost-effective preventative medical care. Additionally, the study found the incremental cost-effectiveness ratio was just over $4,000 for an increase of one quality adjusted life year (QALY) and just over $20,000 for preventing one stroke. If asymptomatic people with AF are detected in this way and given warfarin or other newer blood thinners, the risk of stroke can potentially be reduced by two thirds.

The study, “Feasibility and cost effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies,” appeared in the April 1 online issue of Thrombosis and Haemostasis and was led by Ben Freedman, M.D., professor of cardiology, Concord Hospital Department of Cardiology and Anzac Research Institute, Sydney Medical School, University of Sydney.

 “Community screening using the AliveCor heart monitor in pharmacies has shown to be both feasible and cost-effective in helping physicians identify people with AF, the most common abnormal heart rhythm, which is responsible for a third of all strokes,” said Freedman. “In many cases AF is not known before a stroke, so screening for AF and treating with effective medications could make an impact on reducing the community burden of stroke.”

“We believe these findings have great significance for health providers and should become part of routine practice as this type of screening program is a cost-effective way to identify patients with asymptomatic atrial fibrillation, a condition that can lead to potentially life threatening complications,” said Euan Thomson, president and CEO of AliveCor.

The AliveCor heart monitor is the only U.S. Food and Drug Administration (FDA) cleared mobile ECG recorder that supports both iPhone and Android smartphones. It records, displays (when prescribed or used under the care of a physician), stores and transfers single-channel ECG rhythms wirelessly, using the free AliveECG app. With secure storage in the cloud, users can access their data confidentially anytime, anywhere, and can grant access to their physicians. The heart monitor is available for purchase in the United States by health professionals and consumers.

For more information: www.alivecor.com

Related Content

3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Sponsored Content | Videos | Business| July 13, 2017
Randall Thompson, M.D., professor of medicine at the University of Missouri, Kansas City, attending cardiologist, Mid
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Patient Race, Gender Both Important in Predicting Heart Attack Symptoms in the ER
News | Cath Lab| July 07, 2017
Researchers at the George Washington University (GW) found that certain symptoms are more and less predictive of...
Greater Emphasis Needed on Preventing, Treating Heart Disease in Women
News | Womens Healthcare| July 06, 2017
Women and physicians do not put enough emphasis on cardiovascular disease in women, and a social stigma regarding body...
Heartflow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

HeartFlow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

Technology | CT Angiography (CTA)| July 06, 2017
July 6, 2017 — GE Healthcare and HeartFlow Inc.
Overlay Init